Endocrine hypertension

Journal of the Royal College of Physicians of London

Volumn 32, Issue 2, 1998, Pages 104-108

  Cleland, Stephen J ^a   Connell, John M C ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID;

ACROMEGALY; ALDOSTERONE BLOOD LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUSHING DISEASE; ENDOCRINE DISEASE; HORMONE METABOLISM; HUMAN; HYPERTENSION; HYPOKALEMIA; PHEOCHROMOCYTOMA; POTASSIUM DEPLETION; PRIMARY HYPERALDOSTERONISM; SHORT SURVEY; SODIUM RETENTION; THYROID DISEASE;

ANIMALS; CUSHING SYNDROME; ENDOCRINE SYSTEM DISEASES; FEMALE; GREAT BRITAIN; HUMANS; HYPERTENSION; MALE; PROGNOSIS;

EID: 0031898576     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Fraser R, Davies DL, Connell JMC. Hormones and hypertension. Clin Endocrinol 1989;31:701-46.
2. Fraser R, Connell JMC. Corticosteroids and hypertension. J Hypertension 1991;7:97-107.
3. Greninger P, Tenshert W, Vetter W. Hypertension in Cushing's syndrome. In: Montero F, Biglieri E (eds). Endocrinology of hypertension. London: Academic Press, 1982:105-10.
4. Gordon RD, Zlesak MD, Tunny TT, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993;20:296-8.
5. Lifton RP, Dhuly RG, Powers M, Rich GM, et al. A chimaeric 11β hydroxylase/ aldosterone synthase gene causes glucocorticoid remediable hyperaldosteronism. Nature 1992;355:262-5.
6. Jamieson A, Connell JMC, Fraser R. Glucocorticoid suppressible hyperaldosteronism: from confusion to conclusion. J Mol Endocrinol 1993;10:3-5.
7. Nelson-Williams C, Hansson JH, Schambelan M. Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 1994; 79:407-14.
8. Stewart PM, Carnie JET, Shackleton CHL, Edwards CRW. Syndrome of apparent mineralocorticoid excess - defect in cortisol-cortisone shuttle. J Clin Invest 1988;82:340-9.
9. Jamieson A, Fraser R. Developments in the molecular biology of corticosteroid synthesis and action: implications for an understanding of essential hypertension. J Hypertension 1994;12:503-9.
10. Ross EJ, Griffith DNW. The clinical presentation of phaeochromocytoma. Q J Med 1989;71:485-96.
11. MacDougall IC, Isles CG, Stewart H, Inglis GC, et al. Overnight clonidine suppression tests in the diagnosis and exclusion of phaeochromocytoma. Am J Med 1998;84:993-1000.
12. Ritchie CM, Shendon B, Fraser R, Hadden DR, et al. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990;76:855-67.
13. Streeten DHP, Anderson GH, Howland T, Chiang R, Smulyan H. Effect of thyroid function on blood pressure - recognition of hypothyroid hypertension. Hypertension 1988;11:78-83.
14. Sangal AV, Beevers DG. Parathyroid hypertension. Br Med J 1983;286:498-9.
15. Streeten DHP, Anderson GH. Secondary hypertension - an overview of its causes and management. Drugs 1992; 43:805-19.